FSD Pharma and Prismic Pharmaceuticals have entered into a securities exchange agreement dated April 22, 2019 pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic.
Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).
CASI Pharmaceuticals has announced the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics.
SK Biopharmaceuticals has collaborated with an artificial intelligence (AI)-driven biopharmaceutical firm twoXAR for the discovery and development of first-in-class treatments for non-small cell lung cancer (NSCLC).
LabCorp’s Covance Drug Development segment is set to acquire Envigo’s non-clinical research services business, while Envigo’s Research Models Services business will purchase the Covance Research Products business.
Atomwise, a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease.
Gilead Sciences has entered into a partnership with insitro for the discovery and development of novel therapies for nonalcoholic steatohepatitis (NASH), a chronic form of liver disease.
San Diego-based Allele Biotechnology and Pharmaceuticals, Inc., officially announced a joint research and development agreement with South Korea’s SCM Lifescience Co., Ltd., for the development of diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs).
Catalent has agreed to acquire contract development and manufacturing organization (CDMO), Paragon Bioservices, in a deal valued at around $1.2bn.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.